Critical. Authoritative. Strategic.


CBR is proudly produced & published
by Technews
Issue Date: October 2006

AstraZeneca chooses Verizon Business

1 October 2006

Verizon Business has been awarded a contract to provide AstraZeneca with a flexible, secure network to support the pharmaceutical company's current and future communications requirements in South Africa and internationally.
Verizon will provide a private IP network that will enable AstraZeneca to link its South African operations and add international connectivity as required. Because the network is managed by Verizon Business, AstraZeneca can focus on its core operations without worrying about network provisioning. The managed network services, based on MultiProtocol Label Switching (MPLS) technology, are backed by a full quality of service agreement.
According to Derick Botha at AstraZeneca, a pharmaceutical company, the organisation chose to partner with Verizon Business SA due to its global reach and ability to leverage international solutions effectively for a local market. "We needed to ensure our chosen communications partner could not only correctly service and support our branches nationally, but that they were well positioned to deliver international services when needed. Verizon Business certainly demonstrated these capabilities during the tender process. We are proud to be associated with such a strong brand and proven global expertise."
Angela Gahagan, country manager at Verizon Business SA, says: "Businesses today depend on digital networks for the exchange of critical information to staff, partners, branch offices, suppliers and customers. Control over how this information is transferred and protected is imperative to the efficient functioning of organisations. We have recently strengthened our international service offering with additional capacity in our network. This, combined with our adherence to global best practices and our ability to deliver full communications offerings to both local and international companies, is what made our tender to AstraZeneca so strong."

Others who read this also read these articles

Search Site

Search Directory

  • Search for:


Previous Issues